1. Home
  2. NUVB vs TUYA Comparison

NUVB vs TUYA Comparison

Compare NUVB & TUYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVB
  • TUYA
  • Stock Information
  • Founded
  • NUVB 2018
  • TUYA 2014
  • Country
  • NUVB United States
  • TUYA China
  • Employees
  • NUVB N/A
  • TUYA N/A
  • Industry
  • NUVB Biotechnology: Pharmaceutical Preparations
  • TUYA Computer Software: Prepackaged Software
  • Sector
  • NUVB Health Care
  • TUYA Technology
  • Exchange
  • NUVB Nasdaq
  • TUYA Nasdaq
  • Market Cap
  • NUVB 1.6B
  • TUYA 1.3B
  • IPO Year
  • NUVB N/A
  • TUYA 2021
  • Fundamental
  • Price
  • NUVB $4.62
  • TUYA $2.19
  • Analyst Decision
  • NUVB Strong Buy
  • TUYA Strong Buy
  • Analyst Count
  • NUVB 7
  • TUYA 1
  • Target Price
  • NUVB $8.86
  • TUYA $3.49
  • AVG Volume (30 Days)
  • NUVB 9.4M
  • TUYA 1.1M
  • Earning Date
  • NUVB 11-03-2025
  • TUYA 11-24-2025
  • Dividend Yield
  • NUVB N/A
  • TUYA 4.95%
  • EPS Growth
  • NUVB N/A
  • TUYA N/A
  • EPS
  • NUVB N/A
  • TUYA 0.05
  • Revenue
  • NUVB $26,748,000.00
  • TUYA $318,493,000.00
  • Revenue This Year
  • NUVB $283.17
  • TUYA $10.16
  • Revenue Next Year
  • NUVB $340.98
  • TUYA $12.68
  • P/E Ratio
  • NUVB N/A
  • TUYA $44.54
  • Revenue Growth
  • NUVB 1137.19
  • TUYA 22.29
  • 52 Week Low
  • NUVB $1.54
  • TUYA $1.46
  • 52 Week High
  • NUVB $5.55
  • TUYA $4.63
  • Technical
  • Relative Strength Index (RSI)
  • NUVB 55.23
  • TUYA 33.94
  • Support Level
  • NUVB $4.45
  • TUYA $2.11
  • Resistance Level
  • NUVB $5.17
  • TUYA $2.32
  • Average True Range (ATR)
  • NUVB 0.44
  • TUYA 0.07
  • MACD
  • NUVB -0.05
  • TUYA -0.01
  • Stochastic Oscillator
  • NUVB 44.17
  • TUYA 20.59

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

About TUYA Tuya Inc. each representing one

Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.

Share on Social Networks: